CFO4Life Group LLC Makes New $204,000 Investment in AMETEK, Inc. (NYSE:AME)

CFO4Life Group LLC purchased a new position in AMETEK, Inc. (NYSE:AMEGet Rating) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,387 shares of the technology company’s stock, valued at approximately $204,000.

Several other institutional investors and hedge funds have also made changes to their positions in AME. Louisiana State Employees Retirement System lifted its holdings in AMETEK by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the technology company’s stock valued at $2,132,000 after purchasing an additional 100 shares in the last quarter. Checchi Capital Advisers LLC lifted its holdings in AMETEK by 5.9% during the fourth quarter. Checchi Capital Advisers LLC now owns 1,793 shares of the technology company’s stock valued at $264,000 after purchasing an additional 100 shares in the last quarter. AlphaMark Advisors LLC lifted its holdings in AMETEK by 3.7% during the fourth quarter. AlphaMark Advisors LLC now owns 3,194 shares of the technology company’s stock valued at $470,000 after purchasing an additional 113 shares in the last quarter. Tsfg LLC lifted its holdings in AMETEK by 3.0% during the fourth quarter. Tsfg LLC now owns 3,932 shares of the technology company’s stock valued at $578,000 after purchasing an additional 116 shares in the last quarter. Finally, Brown Advisory Inc. lifted its holdings in AMETEK by 0.5% during the fourth quarter. Brown Advisory Inc. now owns 28,982 shares of the technology company’s stock valued at $4,261,000 after purchasing an additional 132 shares in the last quarter. 86.72% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Anthony James Conti sold 5,160 shares of AMETEK stock in a transaction that occurred on Friday, March 25th. The shares were sold at an average price of $133.37, for a total value of $688,189.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas A. Amato sold 615 shares of the business’s stock in a transaction that occurred on Monday, March 28th. The stock was sold at an average price of $133.03, for a total transaction of $81,813.45. The disclosure for this sale can be found here. Insiders own 0.72% of the company’s stock.

AME has been the topic of several research reports. StockNews.com initiated coverage on shares of AMETEK in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Morgan Stanley decreased their price target on shares of AMETEK from $159.00 to $158.00 and set an “overweight” rating on the stock in a research note on Friday, January 14th. KeyCorp decreased their price target on shares of AMETEK from $155.00 to $145.00 in a research note on Wednesday, May 4th. Zacks Investment Research raised shares of AMETEK from a “sell” rating to a “hold” rating and set a $134.00 price target on the stock in a research note on Tuesday, April 19th. Finally, Robert W. Baird decreased their price target on shares of AMETEK from $156.00 to $140.00 and set a “neutral” rating on the stock in a research note on Tuesday. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $147.60.

Shares of AME traded down $0.05 during trading on Thursday, reaching $120.39. 28,662 shares of the company traded hands, compared to its average volume of 1,097,628. AMETEK, Inc. has a twelve month low of $118.94 and a twelve month high of $148.07. The stock has a market cap of $27.80 billion, a PE ratio of 26.75, a price-to-earnings-growth ratio of 2.42 and a beta of 1.26. The stock has a 50-day simple moving average of $129.56 and a 200-day simple moving average of $135.09. The company has a quick ratio of 0.87, a current ratio of 1.43 and a debt-to-equity ratio of 0.32.

AMETEK (NYSE:AMEGet Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The technology company reported $1.33 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.06. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.46 billion. AMETEK had a net margin of 18.02% and a return on equity of 17.82%. The business’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same period last year, the business earned $1.07 earnings per share. On average, equities research analysts predict that AMETEK, Inc. will post 5.42 EPS for the current year.

AMETEK announced that its board has approved a stock repurchase plan on Friday, May 6th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the technology company to reacquire up to 3.6% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Friday, June 10th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date is Thursday, June 9th. AMETEK’s dividend payout ratio (DPR) is currently 19.64%.

About AMETEK (Get Rating)

AMETEK, Inc manufactures and sells electronic instruments and electromechanical devices worldwide. It operates in two segments, Electronic Instruments (EIG) and Electromechanical (EMG). The company's EIG segment offers advanced instruments for the process, aerospace, power, and industrial markets; process and analytical instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries; and instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets.

Read More

Institutional Ownership by Quarter for AMETEK (NYSE:AME)

Receive News & Ratings for AMETEK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMETEK and related companies with MarketBeat.com's FREE daily email newsletter.